70 related articles for article (PubMed ID: 22139134)
1. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.
Zheng L; Tan W; Zhang J; Yuan D; Yang J; Liu H
Cancer Immunol Immunother; 2014 Jun; 63(6):581-6. PubMed ID: 24668364
[TBL] [Abstract][Full Text] [Related]
2. Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer.
Cohen AS; Geng L; Zhao P; Fu A; Schulte ML; Graves-Deal R; Washington MK; Berlin J; Coffey RJ; Manning HC
Transl Oncol; 2020 Oct; 13(10):100828. PubMed ID: 32652471
[TBL] [Abstract][Full Text] [Related]
3. β-Glucan-Mediated Oral Codelivery of 5FU and Bcl2 siRNA Attenuates Stomach Cancer.
Afrin H; Esquivel SV; Kumar R; Zahid MI; Oporeza B; Rahman MF; Boland T; Nurunnabi M
ACS Appl Mater Interfaces; 2023 Jul; 15(27):32188-32200. PubMed ID: 37350332
[TBL] [Abstract][Full Text] [Related]
4. Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release.
Morese PA; Anthony N; Bodnarchuk M; Jennings C; Martin MP; Noble RA; Phillips N; Thomas HD; Wang LZ; Lister A; Noble MEM; Ward RA; Wedge SR; Stewart HL; Waring MJ
J Med Chem; 2023 Sep; 66(17):12324-12341. PubMed ID: 37647129
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in gastric cancer.
Thiel A; Ristimäki A
APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Taguchi J; Shimizu Y; Ariga S; Goda T; Ohhara Y; Honma R; Noguchi T; Takeuchi S; Kinoshita I; Amano T; Mizumachi T; Kano S; Takahara M; Abe T; Homma A; Dosaka-Akita H
Int J Clin Oncol; 2021 Jan; 26(1):51-58. PubMed ID: 32996023
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group.
Kentepozidis N; Economopoulou P; Liontos M; Kotsakis A; Boukovinas I; Vardakis N; Kontopodis E; Prinarakis E; Skaltsi T; Souglakos J; Georgoulias V
Ann Gastroenterol; 2018; 31(6):698-704. PubMed ID: 30386120
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients.
Zhang F; Yang X; Li L; Sun L; Wang BO; Yu X
Oncol Lett; 2016 Jan; 11(1):173-181. PubMed ID: 26870185
[TBL] [Abstract][Full Text] [Related]
9. S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial.
Du F; Zheng Z; Shi S; Jiang Z; Qu T; Yuan X; Sun Y; Song Y; Yang L; Zhao J; Wang J; Chi Y
Medicine (Baltimore); 2015 Jun; 94(23):e958. PubMed ID: 26061330
[TBL] [Abstract][Full Text] [Related]
10. Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities.
Gu J; Yang J; Chang Q; Liu Z; Ghayur T; Gu J
PLoS One; 2015; 10(5):e0124135. PubMed ID: 25997020
[TBL] [Abstract][Full Text] [Related]
11. Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer.
Ema A; Waraya M; Yamashita K; Kokubo K; Kobayashi H; Hoshi K; Shinkai Y; Kawamata H; Nakamura K; Nishimiya H; Katada N; Watanabe M
Cancer Med; 2015 Jan; 4(1):90-100. PubMed ID: 25154973
[TBL] [Abstract][Full Text] [Related]
12. STAT3 is associated with lymph node metastasis in gastric cancer.
Deng J; Liang H; Zhang R; Sun D; Pan Y; Liu Y; Zhang L; Hao X
Tumour Biol; 2013 Oct; 34(5):2791-800. PubMed ID: 23824569
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Waddell T; Chau I; Cunningham D; Gonzalez D; Okines AF; Okines C; Wotherspoon A; Saffery C; Middleton G; Wadsley J; Ferry D; Mansoor W; Crosby T; Coxon F; Smith D; Waters J; Iveson T; Falk S; Slater S; Peckitt C; Barbachano Y
Lancet Oncol; 2013 May; 14(6):481-9. PubMed ID: 23594787
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells.
Fukuda K; Saikawa Y; Takahashi M; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Kitagawa Y
Int J Oncol; 2012 Apr; 40(4):975-82. PubMed ID: 22139134
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Tanizaki J; Okamoto I; Takezawa K; Tsukioka S; Uchida J; Kiniwa M; Fukuoka M; Nakagawa K
Mol Cancer Ther; 2010 May; 9(5):1198-207. PubMed ID: 20424000
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG
Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788
[TBL] [Abstract][Full Text] [Related]
17. GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer.
Park JE; Jin MH; Hur M; Nam AR; Bang JH; Won J; Oh DY; Bang YJ
Gastric Cancer; 2019 Sep; 22(5):932-940. PubMed ID: 30815759
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
Zhang W; Gordon M; Lenz HJ
Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
